TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70

Benzinga Newsdesk www.benzinga.com Neutral 55.0%

Neg 0% Neu 55% Pos 0%

TD Cowen analyst Joseph Thome maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $75 to $70.